Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
(Campbell, 2007, pp. 2018 -- 2024)
Number of Claims
Independent Claims
1. The method of independent claim one wherein is: that dosages between 75 mg and 81 mg, will not have any kind of significant long-term impact on the individual.
2. The method of independent claim two wherein is: that 50% of respondents, who were given low dosages of aspirin, show little to no positive improvements in their condition.
3. The method of independent claim three wherein is: that women were more than likely, to see the positive effects from taking aspirin in comparison with men.
4. The method of the independent claim number four: is that the long-term effects of taking aspirin; will have a greater impact upon reducing the underlying levels of platelet formation in women. (Campbell, 2007, pp. 2018 -- 2024)
Dependent Claims
1. The method of claim number one wherein is: the use of aspirin therapy was first introduced by Paul Gibson in 1948. Yet, it was not until 30 years later that the benefits of taking aspirin were fully realized.
2. The method of claim number two wherein is: that LL Craven would build off of the ideas of Gibson in 1953, confirming some of the effects of using aspirin to treat coronary artery disease.
3. The method of claim number three wherein is: that there have been various studies all confirming the effectiveness of taking lower dosages of aspirin (with most recommending usage between 30mg and 130 mg).
4. The method of claim number four wherein: is that researchers found those who take dosages of 30 mg to 283 mg, saw a dramatic improvement in the underlying levels of health after a stroke.
5. The method of claim number five wherein: is that other studies have found similar effects as lower...
The method of claim number six wherein: is that 60 different research studies found no effect between changes in the underlying dosage.
7. The method of claim number seven wherein is: that aspirin taking through chewing or other means will help to increase the absorption rate.
8. The method of claim number eight wherein is: a large number of studies have provided, mixed results on the underlying effects of taking aspirin in treating coronary artery disease.
9. The method of claim number nine wherein is: that 60% of doctors believe that lower dosages of aspirin are more effective.
10. The method of claim number ten wherein is: that large clinical trials have not been able to show the effectiveness of using higher levels of dosage.
11. The method of claim number eleven wherein is: that those who have taken lower dosages after a stroke, will have a 14.7% chance of having a second one 2.6 years later, compared with 15.7% for higher dosages.
12. The method of claim number twelve wherein is: that 11 different studies showed similar rates of recurring stoke and heart attack (regardless of the dosage).
13. The method of claim number thirteen wherein is: that patients who received a dosage of 100 mg were able to see the best results from aspirin therapy.
14. The method of claim number fourteen wherein is: that aspirin taken without being chewed or by drinking water, can slow the effects by as much as 12 hours.
15. The method of claim number fifteen wherein is: that those individual who would take aspirin with water, would see the effects on the body within 15 minutes.
16. The method of claim number sixteen wherein is: that…
Bibliography
Campbell, C. (2007). Aspirin Dose for the Prevention of Cardiovascular Disease. Journal of the American Medical Association, 279 (18). 2018 -- 2024.
Healthcare -- Administration and Legal Many vectors -- science, research funding, social acceptance or rejection -- influence how and whether medical technology is eventually adopted into medical praxis (Hogle, et al., 2012). Undergirding the choices and changes is a shared body of ethical standards and law, the establishment of which is often not consensual or efficacious. Any emerging technology can encounter unanticipated social resistance and ethical concerns that can change the
PK = Deltagen Inc. PRXL = Parexel International Corp. Pvt1 = Quintiles Transnational Corp. (privately held) Industry = Biotechnology As of 2005 Source: Yahoo! Finance, April 29, 2007. Figure 1. Financial Performance: Charles River Laboratories vs. Deltagen Inc. And Parexel International Corp. - January 2002 to date. Source: Yahoo! Finance, April 29, 2007. Operating income for 2006 was reported by the company to be $188.2 million compared to $184.7 million for 2005 and its operating margin for 2006
For instance, in the eyes of the courts, an offense's level could be equated to the guideline for the seriousness of a crime. The next aspect of the scorecard was the offender's personal or associative criminal history. Prior offenses dictated a level of conviction frequencies and social offenses. Therefore the personal criminal history of an individual ends up playing a major role in the sentencing guidelines. A person's propensity
Scientific and Political Aspects of Genetically Modified Foods While there is little controversy over many aspects of biotechnology and its application, genetically modified (GM) foods have become the target of intense controversy. This controversy in the marketplace has resulted in a firestorm of public debate, scientific discussion, and media coverage. The countries most affected by this debate are Middle Eastern and third world countries, who stand to reap the benefits of solving
Role of Technology in Corporate and Social Responsibility Insider trading. The insider trading case that has become most prominent is that against Raj Rajaratnam who ran the hedgefund Galleon Group, and was charged along with his co-defendant, Danielle Chiesi, a former consultant with New Castle Funds, LLC ("Insider Trading," 2010). Rajaratnam was convicted of 14 counts of insider trading, which makes this case the largest scheme concocted by a hedge fund
Pharmaceutical industries have to operate in an environment that is highly competitive and subject to a wide variety of internal and external constraints. In recent times, there has been an increasing trend to reduce the cost of operation while competing with other companies that manufacture products that treat similar afflictions and ailments. The complexities in drug research and development and regulations have created an industry that is subject to intense